CAS 639858-32-5

N-Cyclopropyl-2,4-difluoro-5-[[[2-(2-pyridinylamino)-5-thiazolyl]methyl]amino]benzamide

CAS: 639858-32-5

Fórmula: C₁₉H₁₇F₂N₅OS

Pureza: 98%

Peso molecular: 401.433

Ref: IN-DA01ENIM

BMS-605541

CAS: 639858-32-5

BMS-605541

Pureza: ≥98%

Peso molecular: 401.43g/mol

Ref: 54-BUP11014

BMS 605541

CAS: 639858-32-5

Pemetrexed is a chemotherapeutic drug that has been approved for the treatment of cancer. It inhibits the growth of tumor cells by binding to and disrupting the function of the protein kinase, glycogen synthase kinase-3 (GSK-3). Pemetrexed is used to treat cancer in patients who have not responded to other treatments or whose cancer has spread. Pemetrexed has also been shown to inhibit epidermal growth factor receptor (EGFR) signaling, which may be due to its ability to inhibit GSK-3. This drug binds to two sites on GSK-3, which results in inhibition of both GSK-3 and EGFR signaling pathways. The pharmacokinetic properties of pemetrexed have been studied extensively and its action on lung cells has been examined using a cell culture model.

Fórmula: C₁₉H₁₇F₂N₅OS

Pureza: Min. 95%

Peso molecular: 401.4 g/mol

Ref: 3D-PAB85832

BMS-605541

CAS: 639858-32-5

BMS-605541 is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity(Ki=49 nM).

Fórmula: C₁₉H₁₇F₂N₅OS

Pureza: 98.07%

Cor e Forma: Solid

Peso molecular: 401.43

Ref: TM-T26852